Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Vaccines made from a gene-modified virus and a person's dendritic cells may help
the body build an effective immune response to kill tumor cells. Celecoxib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vaccine
therapy together with celecoxib may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving vaccine therapy together with
celecoxib works in treating patients with metastatic nasopharyngeal cancer.